/PRNewswire/ Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment.
/PRNewswire/ Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment.
/PRNewswire/ Biofidelity, a pioneer in precision cancer diagnostics, today praised California Governor Gavin Newsom and the California legislature for the.